Bluestem Biosciences
Omaha, US · Founded 2022 · Delaware corporation · 13 employees on LinkedIn · 2 known investors
Bluestem Biosciences uses an industrial fermentation process with an engineered yeast strain to convert American corn into 3-hydroxypropionic acid (3-HP) and other platform chemicals, offering a domestic alternative to petroleum-based production. Its business model retrofits existing U.S. bioethanol facilities to produce these chemicals at commercial scale, targeting American manufacturing and agricultural supply chains.</parameter> <parameter name="founders">[]
Also known as Bluestem
Founders & leadership
Investors · 2
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2022
▶$5MraisedAug 2022 · 19 investors · BiotechnologyRule 506(b)
- William HagstromExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Bluestem Biosciences is an Omaha, Nebraska-based industrial biotechnology company developing a fermentation platform that converts corn-derived sugars into platform chemicals used in products such as baby care goods, adhesives, paints, coatings and carbon fiber. The company uses a specially developed yeast strain in a fermentation process that it describes as mirroring conventional bioethanol fermentation in simplicity, scalability and reliability, producing high-purity 3-hydroxypropionic acid (3-HP) from whole-kernel corn feedstock.
The company positions its output as a domestic substitute for chemicals that are predominantly derived from petroleum, framing the effort around supply-chain resilience, U.S. manufacturing competitiveness and national security. Rather than building greenfield plants, Bluestem designs its process to run on the equipment and workflows already present at U.S. bioethanol facilities, which it says allows it to reuse more than 90% of an existing facility's infrastructure and thereby reduce capital expenditure and construction time.
Business model
Bluestem's model is built on retrofitting existing American bioethanol facilities rather than constructing new greenfield plants, allowing reuse of over 90% of a plant's existing infrastructure to lower capital expenditure and shorten timelines to commercial-scale production. Corn feedstock is sourced locally from farmers, and the company frames the retrofit as giving ethanol plants an additional revenue stream that is independent of fuel markets.
Latest developments
The company lists open roles and describes itself as expanding, with a leadership team spanning operations, research and development, process design, chemistry, microbial physiology, and government affairs and business development.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company positions itself as a domestic, corn-based alternative to petroleum-derived platform chemicals, claiming cost-competitiveness with legacy petroleum-based production without sacrificing price or performance. It describes the potential market for renewable acrylates as capable of rivaling the size of the entire U.S. ethanol market.
Bluestem attributes its differentiation as much to its business model as to its biology: integrating into the existing industrial footprint of American bioethanol plants, using over 90% of installed infrastructure, in place of capital-intensive greenfield construction, combined with a yeast fermentation route to 3-HP designed to run like a conventional ethanol fermentation.
Technology
The core technology is an industrial fermentation process using a specially developed yeast strain that converts sugars from whole-kernel American corn into high-purity 3-hydroxypropionic acid (3-HP). The company states the process is designed to mimic existing bioethanol fermentations in simplicity, scalability and reliability, and to operate within the equipment and processes already installed at U.S. bioethanol facilities.
Go-to-market
The company approaches the market through retrofits of existing bioethanol facilities and partnership with American farmers for locally sourced corn feedstock. Business development and government affairs inquiries are directed to a dedicated VP of Government Affairs and Business Development.
Buyers of platform chemicals and renewable acrylates used in downstream products including baby care items, adhesives, paints, coatings and carbon fiber; operators of U.S. bioethanol facilities that would host retrofits; and corn growers in Midwest agricultural communities supplying feedstock.
Geography
Headquartered in Omaha, Nebraska, with a stated focus on the American heartland and Midwest bioethanol and agricultural infrastructure, and an intent to supply global markets with corn-derived chemical inputs.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 1
by search overlapCompanies competing with Bluestem Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of Energy | Phase I | 2023 | $199.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structure▸Research sources · 1
primary sources listed
- Bluestem Biosciencesbluestembiosciences.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bluestem Biosciences do?
- Bluestem Biosciences ferments American corn into 3-hydroxypropionic acid and other platform chemicals in retrofitted bioethanol plants.
- Who are Bluestem Biosciences's investors?
- Bluestem Biosciences's investors include Invest Nebraska, Zero Infinity Partners.
- How much funding has Bluestem Biosciences raised?
- Bluestem Biosciences has disclosed $5M raised across 1 round.
- Where is Bluestem Biosciences headquartered?
- Bluestem Biosciences is headquartered in Omaha, US.